Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs

Expert Opinion on Investigational Drugs

Volumn 23, Issue 3, 2014, Pages 375-385

  Tfelt Hansen, Peer C ^a   Pihl, Thomas ^a   Hougaard, Anders ^a   Mitsikostas, Dimos D ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

Dihydroergotamine; Lasmiditan; Migraine; Serotonin; Treatment; Triptans

Indexed keywords

ANIMALS; BENZAMIDES; DRUG ADMINISTRATION ROUTES; HUMANS; MIGRAINE DISORDERS; PIPERIDINES; PYRIDINES; RECEPTORS, SEROTONIN; SEROTONIN RECEPTOR AGONISTS; TRYPTAMINES;

EID: 84894074657     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.861817     Document Type: Review

References (88)

1. The International Classification Of Headache Disorders, 2nd edition. Cephalalgia 1st ed 2004;24:1-160
2. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27(3):193-210
3. Mathers C, Fat DM, Boerma JT. The global burden of disease: 2004 update. 2008
4. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache 2008;48(4):553-63
5. Hawkins K, Wang S, Rupnow MFT. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007;49(4):368-74
6. Sobocki PA, Jonsson B, Wittchen H-UW, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl):1-27
7. Humphrey PPA. The discovery and development of the triptans, a major therapeutic breakthrough. Headache 2008;48(5):685-7
8. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment ofbmigraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, KMA W, editors. The headaches. 3rd edition. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 469-503
9. Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Secular changes in health care utilization and work absence for migraine and tension-type headache: A population based study. Eur J Epidemiol 2005;20(12):1007-14
10. Tfelt-Hansen P. Over-the-counter triptans for migraine: What are the implications? CNS Drugs 2007;21(11):877-83
11. Minet ML, Massiou H. An instrument to assess patient perceptions of satisfaction with acute migraine treatment (EXPERT Study). Headache 2011;51(4):590-601
12. Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: The unmet needs. CNS Drugs 2012;26(5):375-82
13. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994;46(2):157-203
14. Mitsikostas DD, Sanchez del Rio M. Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Rev 2001;35(1):20-35
15. Bruinvels AT, Landwehrmeyer B, Moskowitz MA, Hoyer D. Evidence for the presence of 5-HT1B receptor messenger RNA in neurons of the rat trigeminal ganglia. Eur J Pharmacol 1992;227(3):357-9
16. Durham PL, Russo AF. Serotonergic repression of mitogen-Activated protein kinase control of the calcitonin generelated peptide enhancer. Mol Endocrinol 1998;12(7):1002-9
17. Durham PL, Sharma RV, Russo AF. Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J Neurosci 1997;17(24):9545-53
18. Razzaque Z, Pickard JD, Ma Q-P, et al. 5-HT1B-receptors and vascular reactivity in human isolated blood vessels: Assessment of the potential craniovascular selectivity of sumatriptan. Br J Clin Pharmacol 2002;53(3):266-74
19. Bou J, Gras J, Cortijo J, et al. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21(8):804-12
20. van den Broek RWM, Bhalla P, VanDenBrink AM, et al. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia 2002;22(2):83-93
21. Verheggen R, Hundeshagen AG, Brown AM, et al. 5-HT1B receptormediated contractions in human temporal artery: Evidence from selective antagonists and 5-HT receptor mRNA expression. Br J Pharmacol 1998;124(7):1345-54
22. Amin FM, Asghar MS, Ravneberg JW, et al. The effect of sumatriptan on cephalic arteries: A 3T MR-Angiography study in healthy volunteers. Cephalalgia 2013;33(12):1009-16
23. Nilsson T, Longmore J, Shaw D, et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372(1):49-56
24. Longmore J, Hargreaves RJ, Boulanger CM, et al. Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: Outcome of two independent studies using different experimental protocols. Funct Neurol 1997;12(1):3-9
25. Kaumann AJ, Frenken M, Posival H, Brown AM. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors. Circulation 1994;90(3):1141-53
26. Edvinsson L, Uddman E, Wackenfors A, et al. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: Relationship to clinical effect. Clin Sci 2005;109(3):335-42
27. Longmore J, Razzaque Z, Shaw D, et al. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: Immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol 1998;46(6):577-82
28. Maassenvandenbrink A, van den Broek RW, de Vries R, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Am Acad Neurol 2000;55(10):1524-30
29. Hou M, Kanje M, Longmore J, et al. 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: Colocalization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 2001;909(1-2):112-20
30. Gomez-Mancilla B, Cutler NR, Leibowitz MT, et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 2001;21(7):727-32
31. Ma Q-P. Co-localization of 5-HT(1B/ 1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001;12(8):1589-91
32. Amlaiky N, Ramboz S, Boschert U, et al. Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem 1992;267(28):19761-4
33. Ramadan NM, Skljarevski V, Phebus LA, Johnson KW. 5-HT1F receptor agonists in acute migraine treatment: A hypothesis. Cephalalgia 2003;23(8):776-85
34. Adham N, Kao HT, Schecter LE, et al. Cloning of another human serotonin receptor (5-HT1F): A fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 1993;90(2):408-12
35. Waeber C, Moskowitz MA. Autoradiographic visualisation of [3H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain. Eur J Pharmacol 1995;283(1-3):31-46
36. Waeber C, Moskowitz MA. [3H] sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: An autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995;352(3):263-75
37. Bhalla P, Sharma HS, Wurch T, et al. Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor. Eur J Pharmacol 2002;436(1-2):23-33
38. Lucaites VL, Krushinski JH, Schaus JM, et al. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch Pharmacol 2005;371(3):178-84
39. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42(Suppl 1):3-9
40. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia 2012;32(1):6-38
41. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. J Am Med Assoc 2007;297(13):1443-54
42. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346(8980):923-6
43. Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: Individual patient data meta-Analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254(6):705-12
44. Tfelt-Hansen P. Unpublished clinical trials with sumatriptan. Lancet 2009;374(9700):1501-2
45. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs Adis Int 2000;60(6):1259-87
46. Maassen van den Brink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98(1):25-30
47. Tfelt-Hansen P, Seidelin K, Stepanavage M, Lines C. The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: A double-blind, placebocontrolled, crossover study in normal subjects. Br J Clin Pharmacol 2002;54(1):38-44
48. MacIntyre PD, Bhargava B, Hogg KJ, et al. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993;87(2):401-5
49. Volans GN. Absorption of effervescent aspirin during migraine. Br Med J 1974;4(5939):265-8
50. Tokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol 1984;18(6):867-71
51. Thomsen LL, Dixon R, Lassen LH, et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996;16(4):270-5
52. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebo-controlled, doseranging study versus zolmitriptan tablet. CNS Drugs 2003;17(9):653-67
53. Fuseau E, Petricoul O, Moore KHP, et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002;41(11):801-11
54. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010;30(10):1159-69
55. Farkkila M, Diener H-C, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebocontrolled, parallel-group, dose-ranging study. Lancet Neurol 2012;11(5):405-13
56. Neeb L, Meents J, Reuter U. 5-HT(1F) Receptor agonists: A new treatment option for migraine attacks? Neurotherapeutics 2010;7(2):176-82
57. Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial. Cephalalgia 2010;30(10):1170-8
58. Pilgrim A, Dussault B, Rupniak N, et al. COL-144 an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy. Cephalalgia 2009;29(Suppl 1):24-5
59. Mitsikostas DD, Tfelt-Hansen P. Targeting to 5-HT1F receptor subtype for migraine treatment: Lessons from the past, implications for the future. Cent Nerv Syst Agents Med Chem 2012;12(4):241-9
60. Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: A review of two placebo-controlled phase II trials. J Headache Pain 2012;13(4):271-5
61. Pierce M, Marbury T, O'Neill C, et al. Zelrix: A novel transdermal formulation of sumatriptan. Headache 2009;49(6):817-25
62. Siegel SJ, O'Neill C, Dubé LM, et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res 2007;24(10):1919-26
63. Goldstein J, Smith TR, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 2012;52(9):1402-10
64. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: A meta-Analysis of 53 trials. Lancet 2001;358(9294):1668-75
65. Gallagher R. What do patients want from acute migraine treatment? Cephalalgia 2004;24:Suppl 2:8-15
66. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-Analysis of 53 trials. Cephalalgia 2002;22(8):633-58
67. Tfelt-Hansen PC. The efficacy of transdermal sumatriptan is too low for general use in migraine. Headache 2013;53(5):842-3
68. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998;18(8):532-8
69. Tfelt-Hansen P, Olesen J. Increasing the effect of triptans in migraine. Lancet 2006;368(9544):1313-14
70. Luthringer R, Djupesland PG, Sheldrake CD, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol 2009;61(9):1219-28
71. Djupesland PG, Skretting A, Winderen M, Holand T. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope 2006;116(3):466-72
72. Obaidi M, Offman E, Messina J, et al. Improved pharmacokinetics of sumatriptan with Breath PoweredTM nasal delivery of sumatriptan powder. Headache 2013;53(8):1323-33
73. Djupesland PG, Docekal P; Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-Actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia 2010;30(8):933-42
74. Cady R, Messina J, Carothers J, Mahmoud R. Efficacy and safety of a novel Breath-PoweredTM powder sumatriptan intranasal treatment for acute migraine [Abstract]. Abstracts of the 2013 International Headache Congress; 27-30 June 2013; Boston, MA, USA. Cephalalgia 2013;33(8 Suppl):21-2
75. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008;28(8):877-86
76. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006;46(Suppl 4):S171-81
77. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache 2008;48(3):355-67
78. Wyss PA, Rosenthaler J, Nuesch E, Aellig WH. Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjects. Eur J Clin Pharmacol 1991;41(6):597-602
79. Tfelt-Hansen P, Saxena P. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch K, editors. The headaches. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 459-67
80. Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 1984;26(4):463-70
81. Dahlof C, Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache 2012;52(4):707-14
82. de Hoon JN, Poppe KA, Thijssen HH, et al. Dihydroergotamine: Discrepancy between arterial, arteriolar and pharmacokinetic data. Br J Clin Pharmacol 2001;52(1):45-51
83. Humbert H, Cabiac MD, Dubray C, Lavene D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther 1996;60(3):265-75
84. Lindblad B, Abisch E, Bergqvist D. The pharmacokinetics of subcutaneous dihydroergotamine with and without a dextran 70 infusion. Eur J Clin Pharmacol 1983;24(6):813-18
85. Kori S, Zhang J, Kellerman D. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors [Abstract]. J Headache Pain 2013;14(Suppl 1):P75
86. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009;49(6):826-37
87. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache 2011;51(4):507-17
88. Tfelt-Hansen PC. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review. Cephalalgia 2013;33(13):1122-31